Excerpt

At the request of the Alzheimer’s Association, the Institute of Medicine’s (IOM’s) Forum on Neuroscience and Nervous System Disorders planned and hosted a 2-hour public workshop at the 2010 International Conference on Alzheimer’s Disease (ICAD). Held in Honolulu, HI, on July 12, 2010, the session was designed to explore future opportunities to leverage the Alzheimer’s Disease Neuroimaging Initiative (ADNI), with particular focus on the second phase of the ADNI project, ADNI 2. Panelists from industry, academia, and government examined the key elements of success of the research partnerships established as a result of ADNI, and contemplated the establishment of future multisector efforts to explore central nervous system developmental and neurodegenerative disorders. This report is limited to a review of workshop speaker presentations and commentary by panelists.

Contents

• The National Academies
• Workshop on ADNI: What's Next? State-of-the-Art Methods for Exploring CNS Developmental and Neurodegenerative Disorders Research Planning Committee
• Institute of Medicine Forum on Neuroscience and Nervous System Disorders
• Reviewers
• Workshop Summary
  • INTRODUCTION
  • BACKGROUND
  • SESSION OVERVIEW
  • KEY ELEMENTS OF ADNI: WHAT LESSONS CAN BE LEARNED FOR MOVING FORWARD?
  • MOVING FORWARD: OPPORTUNITIES AND FUTURE SYNERGIES FOR ADNI 2
• Appendixes
  • Appendix A References
  • Appendix B Workshop Agenda

Rapporteurs: Theresa Wizemann, Diana E Pankevich, and Bruce M Altevogt

This project was supported by contracts between the National Academy of Sciences and the Alzheimer’s Association; AstraZeneca Pharmaceuticals, Inc.; CeNeRx Biopharma; the Department of Health and Human Services’ National Institutes of Health (NIH, Contract No. N01-OD-4-2139) through the National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Eye Institute, NIH Blueprint for Neuroscience Research, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke; Eli Lilly and Company; GE Healthcare, Inc.; GlaxoSmithKline, Inc.; Johnson & Johnson Pharmaceutical Research and Development, LLC; Merck Research Laboratories; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. OIA-0753701); the Society for Neuroscience; and Wyeth Research, Inc.

Suggested citation:

IOM (Institute of Medicine). 2011. Future Opportunities to Leverage the Alzheimer’s Disease Neuroimaging Initiative: Workshop Summary. Washington, DC: The National Academies Press.

The views presented in this publication are those of the editors and attributing authors and do not necessarily reflect the view of the organizations or agencies that provided support for this project.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.